Risks
4 risks
Risk Intelligence
Regulatory delays in acquisition closures
View Risks →Entero Healthcare Solutions Limited — Q1 FY26
Entero Healthcare delivered a strong Q1 FY26 with revenue of ₹1,440 crore, up 28% YoY (31% like-to-like), driven by 15% organic growth (1.6x IPM) and 16% from M&A.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Entero Healthcare delivered a strong Q1 FY26 with revenue of ₹1,440 crore, up 28% YoY (31% like-to-like), driven by 15% organic growth (1.6x IPM) and 16% from M&A. EBITDA grew 66% YoY to ₹50 crore, with margins expanding 82 bps to 3.6%, despite annual wage hikes. PAT rose 47% to ₹30 crore. Gross margins improved 83 bps to 9.9% on better mix and procurement. Management reiterated FY26 guidance of 30% revenue growth and 4%+ EBITDA margins, with operating leverage expected from Q2 onward as seasonal demand picks up. Working capital days targeted to reduce from 66 to 60 by year-end. Risk: Integration of recent acquisitions may face regulatory delays (e.g., drug license site outage).
एंटरो हेल्थकेयर ने वित्त वर्ष 2026 की पहली तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई ₹1,440 करोड़ रही, जो पिछले साल से 28% ज्यादा है। इसमें 15% अपने कारोबार से और 16% नई कंपनियों को खरीदने से बढ़ोतरी हुई। मुनाफा (EBITDA) 66% बढ़कर ₹50 करोड़ हो गया। कंपनी ने सालाना तनख्वाह बढ़ोतरी के बावजूद मुनाफा बढ़ाया। शुद्ध मुनाफा (PAT) 47% बढ़कर ₹30 करोड़ रहा। कंपनी का कहना है कि इस साल कमाई 30% और मुनाफा 4% से ज्यादा रहेगा। हालांकि, नई कंपनियों को जोड़ने में दवा लाइसेंस जैसी देरी का खतरा है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Retailers served
71,000
+18% YoY
Increased from 60,000 in Q1 FY25, reflecting continued customer acquisition.
Hospitals served
2,500+
flat QoQ
Hospital count stable sequentially; focus on wallet share growth.
SKUs handled
74,700
+24% YoY
Expanded product range, including higher-margin categories like medical devices.
Working capital days
66 days
-5 days YoY
Reduced from ~71 days a year ago; targeting 60 days by FY26 end.
Fast read
Guidance and risk preview
Management expects full-year revenue growth of 30%, including ~15% organic and ~15% from M&A, with ~₹500 crore of acquired revenue recognized.
Closure of two announced acquisitions delayed due to drug license site outage, impacting revenue recognition timing.
View Risks →